Certara, Inc.

Certara, Inc. announced it will release its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Following the release, company management will host a conference call at 8:30 AM ET to discuss the results. Investors interested in participating are required to register online, and a webcast of the event will be available on the company's investor relations website.

Certara, Inc. announced that John E. Gallagher III, Senior Vice President and Chief Financial Officer, tendered his resignation to pursue another opportunity, effective July 14, 2026. The company has initiated a search for his successor. Concurrently, Certara appointed Faiz Mohammed, its Senior Vice President of Finance and Treasurer since 2018, as Interim Chief Financial Officer, effective July 15, 2026. The company also reaffirmed its full-year 2026 financial guidance.

Certara, Inc. announced that its Chief Financial Officer, John Gallagher, will resign effective July 14, 2026. The company has launched a search for a new CFO. Faiz Mohammed, Certara's Senior Vice President of Finance and Treasurer, will serve as Interim CFO upon Mr. Gallagher's departure. Certara also took the opportunity to reaffirm its 2026 financial guidance.

Certara, Inc. reported a net loss of $(8.8) million for the first quarter of 2026, a significant decline from a net income of $4.7 million in the prior year. Revenues saw a modest increase of 0.86% to $106.9 million. Net cash provided by operating activities also decreased, while the company executed a $40.0 million common stock repurchase program during the quarter.

Certara, Inc. announced the completion of the sale of its global medical writing and related regulatory services business to Veristat, LLC for $85.0 million in cash, with additional contingent consideration. Concurrently, the company reported its first quarter 2026 financial results, showing a 1% increase in total revenue to $106.9 million but a net loss of $8.8 million, down from a net income of $4.7 million in the prior year. Certara also updated its full-year 2026 guidance to reflect the divestiture, expecting revenue between $395 million and $405 million.

Certara reported first quarter 2026 financial results, with total revenue increasing 1% to $106.9 million, but a net loss of $8.8 million compared to a net income in the prior year. The company completed the divestiture of its global medical writing and related regulatory services business for $85.0 million cash, with potential additional consideration. This strategic move aims to sharpen execution and position Certara for long-term growth, with updated 2026 guidance reflecting the divestiture.

Certara, Inc. has entered into a Purchase Agreement with Veristat, LLC to divest its global medical writing and related regulatory services business. The transaction involves Certara selling the equity interests of certain subsidiaries and related assets for an aggregate cash consideration of $100 million, subject to post-closing adjustments. Additionally, Certara could receive up to $35 million in contingent earn-out consideration based on the business's future financial performance. The closing is subject to customary conditions, including internal reorganization steps.

Certara, Inc. announced a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for up to $135 million. This divestment aims to sharpen Certara's focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions, accelerating investment in AI-integrated modeling and simulation. The divested business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025 and is expected to close in Q2 2026.

Certara, Inc. (CERT) has scheduled the release of its first quarter 2026 financial results for before market open on Monday, May 11, 2026. Following the release, company management will host a conference call at 8:30 AM ET to discuss the results and provide insights into the company's performance. This announcement is crucial for investors to mark their calendars and prepare for the upcoming earnings report, which will offer a detailed look into Certara's operational and financial health for the quarter. A live and archived webcast will be available on the company's investor relations website for those unable to attend the live call.